In This Issue: Volume 33, No. 3

Check out what's new in schizophrenia research, personality disorders, patient education, integrative psychiatry, addiction, and more.

Related Videos
Related Content

Rx Evolution: An Ununified Model of MDD and Pharmacological Paradigms

February 6th 2023

Blue Light Blockers: A Behavior Therapy for Mania

October 7th 2021

From the Pages of Psychiatric Times: January 2023

January 31st 2023

Treating ‘Morally Objectionable’ Patients

September 27th 2021

Positive Results from Phase 2a Trial of Psychedelic for Major Depressive Disorder

January 25th 2023

Recovery-Oriented Cognitive Therapy: Changing Lives With a Whole-Person Approach

January 23rd 2023

Rx Evolution: An Ununified Model of MDD and Pharmacological Paradigms

February 6th 2023

Blue Light Blockers: A Behavior Therapy for Mania

October 7th 2021

From the Pages of Psychiatric Times: January 2023

January 31st 2023

Treating ‘Morally Objectionable’ Patients

September 27th 2021

Positive Results from Phase 2a Trial of Psychedelic for Major Depressive Disorder

January 25th 2023

Recovery-Oriented Cognitive Therapy: Changing Lives With a Whole-Person Approach

January 23rd 2023

Rx Evolution: An Ununified Model of MDD and Pharmacological Paradigms

February 6th 2023

Blue Light Blockers: A Behavior Therapy for Mania

October 7th 2021

From the Pages of Psychiatric Times: January 2023

January 31st 2023

Treating ‘Morally Objectionable’ Patients

September 27th 2021

Positive Results from Phase 2a Trial of Psychedelic for Major Depressive Disorder

January 25th 2023

Recovery-Oriented Cognitive Therapy: Changing Lives With a Whole-Person Approach

January 23rd 2023
Advertise
Contact Us
Editorial
Terms and Conditions
Privacy Policy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.